Right to Adequate Iron Status

“Iron deficiency without anaemia is the most common — and most commonly missed — nutritional deficiency in the industrialised world. Its symptoms are attributed to almost anything else.” — Auerbach & Adamson, American Journal of Hematology, 2016

From chlorosis to the modern era

Iron is the oldest recognised nutritional deficiency in Western medicine. Hippocrates, in the fourth century BCE, described the pallor and lassitude of women whose menstrual losses had exceeded what their diet returned. The disease was named chlorosis — the “green sickness” — and treated, from the seventeenth century onward, with iron filings dissolved in wine. In 1832, the French physician Pierre Blaud formulated Blaud’s pill, a compressed dose of ferrous sulphate and potassium carbonate that reliably restored colour and vigour to young women who had, until then, been dismissed as constitutionally weak. The therapeutic effect of iron on anaemia was thus one of the earliest reproducible interventions in the history of medicine.

In 1937, the Czech biochemist Vilém Laufberger isolated ferritin from horse spleen, giving science its first molecular grip on iron storage. In the 1970s, James D. Cook and colleagues at the University of Kansas established serum ferritin as a clinical marker of body iron stores — a landmark that made non-invasive assessment of iron status possible for the first time. In 2001, Tomas Ganz and Elizabeta Nemeth, at UCLA, identified hepcidin as the master regulatory hormone of systemic iron homeostasis, closing the loop between inflammation and iron availability that had puzzled clinicians for a century.

Each of these advances refined the tool. None of them corrected the interpretation. In 2016, Michael Auerbach, whose clinical practice with intravenous iron spans four decades, wrote that iron deficiency without anaemia remained the most common missed diagnosis in his experience — routinely attributed to depression, anxiety, deconditioning, or the ordinary tiredness of being alive. In 2021, Sant-Rayn Pasricha and colleagues published the Lancet seminar on iron deficiency, arguing for a diagnostic threshold of 30 µg/L for serum ferritin — twice the value still printed on most laboratory reports.

The tools are honest. The routine reading of them is not.

Why the honest test is defeated in routine practice

The multi-marker panel — iron studies

Iron is one of the few nutrients for which the medical field has developed, and knows how to use, a proper multi-marker functional assessment. The full panel — serum ferritin, serum iron, transferrin, transferrin saturation, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) to correct for the inflammatory rise of ferritin — is capable of answering the question of tissue iron adequacy with a precision that most nutritional assessments cannot approach. As a template of what nutritional testing should look like, the iron panel is the field’s honest case.

Behind Every Test, an Industry names iron as exactly this: the anchor case. That claim stands.

What is ordered — and what is not

In primary care, the panel that could be ordered and the panel that is ordered are not the same. In most non-specialist settings, serum ferritin alone is drawn. Transferrin saturation is sometimes added; sTfR and CRP-corrected ferritin, almost never. The result is that the interpretive burden is placed entirely on a single number — ferritin — which is itself an acute-phase reactant and rises with any inflammation, obscuring true depletion in patients with concurrent chronic inflammation, obesity, or infection.

The threshold problem

The World Health Organization’s cutoff for iron deficiency in non-pregnant adult women is a serum ferritin of 15 µg/L. Many clinical laboratories print reference ranges that start below this — 10, 12 µg/L, depending on the platform and the population whose distribution generated the interval. Zuguo Mei and colleagues at the US CDC (American Journal of Clinical Nutrition, 2017) proposed 25 µg/L as the healthy-adult floor, on the basis of the value at which iron-dependent haematological markers begin to shift. Pasricha and coauthors argue for 30 µg/L. Auerbach’s clinical practice treats symptomatic iron deficiency without anaemia at ferritin values up to 50 µg/L, often higher in athletes and menstruating women. In restless legs syndrome, the International Restless Legs Study Group consensus favours around 75 µg/L. In cognitive and mood symptoms, several smaller studies point to functional improvement above 100 µg/L.

The distance between 10–15 and 30–100 is where the failure of the test lives. It is not a failure of biochemistry. It is a failure of interpretation.

See The Ferritin Threshold for the full argument on the number that unmakes the field’s honest tool.

Iron deficiency without anaemia

Iron deficiency anaemia is the recognised endpoint: haemoglobin falls, the complete blood count declares itself, the reticulocyte response confirms. Iron deficiency without anaemia (IDWA) is what the routine panel does not name. Ferritin can be at 8 µg/L while haemoglobin still reads 130 g/L. Stores are depleted; compensatory erythropoiesis is still holding. The patient is severely deficient in the sense that matters biologically — reduced tissue iron for oxidative phosphorylation, for dopaminergic neurotransmission, for thyroid peroxidase, for immune function — while the anaemia panel returns “normal.”

The clinical presentation of IDWA is precisely what primary care most consistently attributes to something else: unexplained tiredness disproportionate to activity, hair loss, restless legs at night, tachycardia and palpitations, brain fog, cold extremities, breathlessness on stairs, brittle nails, unusual cravings for ice or earth (pagophagia, geophagia). The populations most affected are menstruating women — particularly those with heavy menstrual bleeding — endurance athletes, regular blood donors, patients with coeliac or inflammatory bowel disease, and adolescents through their growth spurt.

Iron: far more than haemoglobin

The public-facing story of iron is a story about red blood cells. The biological story is much larger.

Oxidative phosphorylation

Iron is a structural component of the cytochromes of the mitochondrial electron transport chain — Complex I, Complex II, Complex III, Complex IV — and of aconitase in the Krebs cycle. Every ATP produced by aerobic respiration in every cell of the body passes through iron-sulfur clusters. When tissue iron falls, cellular energy production falls with it, before the red cell count ever registers a change. The exhaustion of iron deficiency without anaemia is not psychosomatic. It is bioenergetic.

DNA synthesis

Ribonucleotide reductase, the enzyme that converts ribonucleotides to deoxyribonucleotides — the rate-limiting step in DNA synthesis and repair — is an iron-dependent enzyme. Every dividing cell in the body, from bone marrow to gut epithelium to hair follicle, requires iron for replication. The hair loss of iron deficiency is not a cosmetic side-effect; it is the visible face of an impaired synthesis process.

Dopamine and the brain

Tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, requires iron as a cofactor. Iron is also essential for the dopamine D2 receptor and for myelin synthesis by oligodendrocytes. John L. Beard and colleagues at Penn State documented, across two decades of work, the cognitive and behavioural consequences of iron deficiency in infants, adolescents, and adults — effects that persist even after ferritin is restored, if the deficit occurred during a developmental window. Restless legs syndrome is now understood as a disorder of brain iron availability, treated at ferritin thresholds far above what primary care considers deficient.

Thyroid function

Thyroid peroxidase (TPO), the enzyme responsible for the iodination of thyroglobulin and thus the synthesis of thyroid hormones, is a haem-dependent enzyme. Iron deficiency reduces circulating T4 and T3 and blunts the response to iodine repletion. A patient with concurrent iron deficiency and mild hypothyroidism cannot be adequately treated for one without the other.

Immune function

The relationship between iron and infection is not linear. Eugene Weinberg, of Indiana University, spent his career documenting the concept of nutritional immunity — the withholding of iron from pathogens by the host as a defence mechanism, orchestrated in modern understanding by hepcidin. This complexity is real, and it is the reason iron repletion in the setting of active infection requires clinical judgment. It is not, however, a reason to withhold iron from the non-infected symptomatic patient at ferritin 8.

A staggering inventory of associated conditions

The list of conditions in which iron deficiency has been documented as a contributor is long enough to be received as implausible. Each association is peer-reviewed.

Heavy menstrual bleeding

The population most systematically underdiagnosed is women with heavy menstrual bleeding. The medical literature is explicit that HMB, defined as blood loss exceeding 80 mL per cycle, produces cumulative iron loss that dietary iron alone cannot replace. In practice, most women whose iron reserves are being drained monthly do not receive full iron studies. They receive an SSRI for the fatigue, a beta-blocker for the palpitations, and reassurance that their haemoglobin is normal.

Restless legs and cognitive symptoms

The International Restless Legs Study Group consensus documents identify a serum ferritin below 75 µg/L as sufficient indication for iron repletion in symptomatic RLS. Primary care rarely reads ferritin above 15 as deficient. The gap is measured in a factor of five, and in years of untreated symptoms.

The developmental window

Beard’s work established that iron deficiency during infancy, adolescence, and pregnancy produces effects on cognitive and motor development that do not fully reverse after ferritin is repleted. The threshold problem is thus not merely a matter of adult symptomatic burden. It is a matter of what a generation loses when the number printed on the lab report is set at the wrong place.

Health policies facing their own failure

The dietary fortification framework

Iron is one of the most heavily supplemented nutrients in the public-health arsenal. Mandatory fortification of milled grain is in place in approximately eighty-five countries. Infant formula and prenatal supplements deliver measured doses. The red-meat lobby carries the message that adequate iron requires adequate red meat. The framework’s coherence depends on a specific claim: that deficiency, in the fortified world, is rare.

Set the threshold at 15 µg/L and the claim is defended. Set the threshold at 30 or 50 — the values the specialty literature supports — and a substantial fraction of premenopausal women in industrialised populations are revealed as deficient. The fortification framework does not, in fact, cover the population it claims to cover. The threshold is where the failure is hidden.

The intravenous iron market

Downstream of the threshold, the intravenous iron market — ferric carboxymaltose (Injectafer, Ferinject), ferric derisomaltose (Monoferric), ferumoxytol (Feraheme) — is expensive per unit and requires specialist infrastructure. A low ferritin threshold contains referral. A patient at ferritin 12 is told to eat spinach. A patient at ferritin 4, hospitalised for anaemic collapse, is referred for infusion. The threshold is the gate that separates the two, and it is set high enough that the flow through the gate remains manageable for the specialist supply.

The industries do not, in most cases, actively lobby for a low threshold. They benefit from its inertia. And a technical detail compounds it: the reference range on the lab printout is generated by each laboratory from its local population’s percentile distribution — which, in a population where iron deficiency is widespread, is itself depressed. A ferritin of 12 sits inside the population’s own lower percentile. The reference range is the population, not the biology. And the population is, on this specific nutrient, deficient.

The vicious cycle in primary care

A menstruating woman consults for fatigue, palpitations, hair loss, and difficulty concentrating. Ferritin is ordered — alone — and returns at 14. She is told her iron is normal. The fatigue is attributed to stress; an SSRI is offered. The palpitations lead to a Holter monitor and a beta-blocker. The hair loss is referred to dermatology. The concentration difficulty is named as ADHD or perimenopause. Five years pass. She encounters, often by accident, the possibility that ferritin has a functional threshold above the reference range. A repeat draw returns 8. Iron repletion, oral for months and subsequently intravenous, produces improvement in weeks that she describes as recovering a decade of lost life.

The consistency of this narrative across thousands of individual accounts is data of a specific kind. It maps the population failed by the routine reading of an honest test.

What the experts say — in their own words

Michael Auerbach — Four decades of clinical intravenous iron

Auerbach’s practice at Auerbach Hematology Oncology in Baltimore has treated tens of thousands of patients with intravenous iron across the arc of the field’s evolution. His editorials and reviews in American Journal of Hematology, Haematologica, and Blood argue consistently for treatment of symptomatic iron deficiency without anaemia at ferritin thresholds well above the WHO cutoff:

“The dogma that a normal haemoglobin excludes clinically relevant iron deficiency has caused more diagnostic delay in my practice than any other single misconception.”

Sant-Rayn Pasricha — The Lancet seminar

Head of the Population Health and Immunity Division at WEHI in Melbourne, Pasricha coordinated the Lancet 2021 seminar on iron deficiency:

“Serum ferritin concentration less than 30 µg/L is the most sensitive and specific indicator of iron deficiency, with a positive predictive value approaching 100%.”

The value has been in the literature for years. It has not migrated into the laboratory reference ranges.

Zuguo Mei — CDC

Mei and colleagues, using NHANES and international survey data, established that iron-dependent haematological markers begin to shift at ferritin values well above the WHO threshold of 15 µg/L:

“A serum ferritin threshold of 25 µg/L identifies iron insufficiency in apparently healthy adults with higher sensitivity than the WHO threshold, without loss of specificity.”

Clara Camaschella — Physiology and pathology of iron

Camaschella, at San Raffaele in Milan, has written the modern reference reviews on iron disorders for New England Journal of Medicine and Blood. Her work is the standard clinical reference for iron-refractory iron deficiency anaemia (IRIDA) and for the hepcidin-driven anaemia of chronic disease.

Tomas Ganz and Elizabeta Nemeth — Hepcidin

The 2001 identification of hepcidin as the master regulator of systemic iron homeostasis, at UCLA, reframed a century of clinical observation about iron and inflammation. Ganz and Nemeth’s continuing work at the UCLA Center for Iron Disorders remains the reference on the physiology.

James D. Cook — Ferritin as a clinical marker

Cook’s work at the University of Kansas in the 1970s established the correlation between serum ferritin and body iron stores that underpins all subsequent clinical use of the marker. He was also among the first to note that the thresholds derived from population distributions systematically underestimate true deficiency.

John L. Beard — Iron and the brain

Beard’s twenty years of work at Penn State documented that iron deficiency in developmental windows produces cognitive and behavioural effects that persist after biochemical repletion — a finding that transforms the threshold question from a question of adult symptom control into a question of generational damage.

Timeline: an honest tool, dishonestly read

References

1. Auerbach & Adamson — How we diagnose and treat iron deficiency anemia — PubMed
2. Pasricha, Tye-Din, Muckenthaler & Swinkels — Iron deficiency — Lancet Seminar 2021 — PubMed
3. Mei et al. — Physiologically based serum ferritin thresholds for iron deficiency — AJCN 2017 — PubMed
4. Camaschella — Iron-deficiency anemia — NEJM 2015 — PubMed
5. Ganz & Nemeth — Hepcidin and iron homeostasis — PubMed
6. Cook, Skikne & Baynes — Serum ferritin as an index of iron stores — PubMed
7. Beard — Iron biology in immune function, muscle metabolism and neuronal functioning — J Nutr — PubMed
8. Laufberger — Sur la cristallisation de la ferritine — Bull Soc Chim Biol 1937
9. Allen et al. — International Restless Legs Study Group consensus on iron and RLS — PubMed
10. Auerbach & Ballard — Clinical use of intravenous iron — Haematologica — PMC
11. WHO — Serum ferritin concentrations for the assessment of iron status — WHO
12. Weinberg — Iron withholding as a defense strategy — PubMed
13. Zimmermann & Köhrle — The impact of iron and selenium deficiencies on thyroid function — PubMed
14. Lozoff & Georgieff — Iron deficiency and brain development — PubMed
15. Cappellini, Musallam & Taher — Iron deficiency anaemia revisited — J Intern Med — PubMed
16. Muñoz, García-Erce & Remacha — Disorders of iron metabolism, part II — J Clin Pathol — PubMed
17. Krayenbuehl et al. — Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women — Blood 2011 — PubMed
18. Verdon et al. — Iron supplementation for unexplained fatigue in nonanaemic women — BMJ 2003 — PubMed
19. Vaucher et al. — Effect of iron supplementation on fatigue in nonanemic menstruating women — CMAJ 2012 — PubMed
20. Camaschella — New insights into iron deficiency and iron deficiency anemia — PubMed